ABT - Abbott Laboratories
261
$107.19
-$1.30 (-1.198%)
$107.01
-$0.18 (-0.167%)
Score3.79/5
Price Targets
54.8%
26.9%
6.5%
Most Recent Recommendations
Revenue Estimate
- Past Revenue
- Avg
- High
- Low
EPS Estimate
- Past EPS
- Avg
- High
- Low
Revenue Estimate as % change
| 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
|---|---|---|---|---|---|---|---|---|
| Low | 6.17% | 7.20% | 5.95% | 8.11% | 7.68% | 7.01% | 6.98% | 7.11% |
| Avg | 7.00% | 7.39% | 6.93% | 6.74% | 7.25% | 6.55% | 6.98% | 7.11% |
| High | 7.59% | 7.84% | 7.30% | 5.93% | 7.07% | 5.74% | 6.98% | 7.11% |
EPS Estimate as % change
| 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
|---|---|---|---|---|---|---|---|---|
| Low | 9.53% | 8.17% | 5.09% | -0.31% | 30.1% | 9.64% | 9.67% | 9.72% |
| Avg | 10.4% | 9.99% | 9.49% | 7.34% | 13.7% | 8.89% | 9.67% | 9.72% |
| High | 11.4% | 10.6% | 11.1% | 7.90% | 10.3% | 7.82% | 9.67% | 9.72% |
Recommendation Trends
- Strong Sells
- Sells
- Holds
- Buys
- Strong Buys
Latest Analyst Ratings
Institution | Action | Grade | Old Grade | Date |
|---|---|---|---|---|
| Citigroup | Maintain | Buy | Buy | 2026-03-11 |
| Barclays | Maintain | Overweight | Overweight | 2026-02-02 |
| RBC Capital | Maintain | Outperform | Outperform | 2026-01-23 |
| Bernstein | Maintain | Outperform | Outperform | 2026-01-23 |
| Citigroup | Maintain | Buy | Buy | 2026-01-23 |
| Oppenheimer | Maintain | Outperform | Outperform | 2026-01-23 |
| Piper Sandler | Maintain | Overweight | Overweight | 2026-01-23 |
| Evercore ISI Group | Maintain | Outperform | Outperform | 2026-01-23 |
| BTIG | Maintain | Buy | Buy | 2026-01-23 |
| Bernstein | Maintain | Outperform | Outperform | 2026-01-09 |